Crinetics Approach

Philip Harris, FRCP, Ph.D.

Dr. Harris joined our scientific advisory board in February 2019, bringing expertise as both a distinguished clinical endocrinologist and more than 16 years of leadership experience in industry in the fields of endocrinology, neuroendocrine tumors, and endocrine-related oncology. He currently serves as Chief Medical Officer of ITM Isotopen Technologien München AG and is responsible for providing clinical leadership to ITM’s radiopharmaceutical development platform. Prior to ITM, he was Vice President at Ipsen from 2007 to 2017, with leading roles in Scientific Affairs, Translational Sciences, and Medical Science. He was also Senior Director of Clinical Development at Pfizer from 2004 to 2007. Prior to Pfizer, he served as Director of Global Medical Affairs at Pharmacia from 2002 to 2004. Before moving to industry, he held an academic consultant appointment at King’s College Hospital, London in internal medicine and adult endocrinology. He holds a Bachelor of Medicine & Surgery and a PhD from the University of Wales.